

05-02-03

1642
BPP 500

MAY 01 2003

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Application Number 09/806,125

Filing Date 3/28/2001

First Named Inventor MATSUTANI, Eisui

Group Art Unit 1642

Examiner Name Rawlings, S.

Total Number of Pages in This Submission 22

Attorney Docket Number 2556 USOP

ENCLOSURES (check all that apply)

- ☐ Fee Transmittal Form
☐ Fee Attached
☐ Amendment / Reply
☐ After Final
☐ Affidavits/declaration(s)
☐ Extension of Time Request
☐ Express Abandonment Request
☐ Information Disclosure Statement
☐ Certified Copy of Priority Document(s)
☒ Response to Missing Parts/Incomplete Application
☐ Response to Missing Parts under 37 CFR 1.52 or 1.53

- ☐ Assignment Papers (for an Application)
☐ Drawing(s)
☐ Licensing-related Papers
☐ Petition
☐ Petition to Convert to a Provisional Application
☐ Power of Attorney, Revocation Change of Correspondence Address
☐ Terminal Disclaimer
☐ Request for Refund
☐ CD, Number of CD(s) _____

- ☐ After Allowance Communication to Group
☐ Appeal Communication to Board of Appeals and Interferences
☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
☐ Proprietary Information
☐ Status Letter
☒ Other Enclosure(s) (please identify below):
 Return Postcard.
 Certificate of Express Mailing
 Submission of CRF of Sequence Listing
 Notification to Comply


Remarks

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account 500799.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENTFirm
or
Individual name

Mark Chao, Ph.D., JD, Reg. No. 37,293

Signature



Date

5/1/03

CERTIFICATE OF MAILINGI hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as **EXPRESS** mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: 5/1/03

Typed or printed name

Gail L. Winokur

Signature



Date

5/1/03

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXPRESS MAIL #EV 193976441 US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 09/806,125

Filed: 3/28/2001

1st Inventor: MATSUTANI, Eisuya

For: Agent that retards the transformation of hormone-dependent cancer to non-hormone dependent cancer

Atty. Dkt. No. 2556 USOP

Art Unit: 1642

Examiner: Rawlings, S.

Allowed:

Batch:

Paper No.:

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10

USPS EXPRESS MAIL LABEL. No. EV 193976941 US

RECEIVED

DATE IN: May 1, 2003

MAY 06 2003

Itemized Papers/Items:

TECH CENTER 1600/2900


1. This Postcard and Certificate of Express Mailing (2 pages)
2. Transmittal Form (1 page X 2)
3. Response to Notice to Comply with Sequence Listing Requirements (1 page), Submission of CRF of Sequence Listing (8 pages), IBM PC/AT format disk containing the CRF of the Sequence Listing, and copy of Notification to Comply (9 pages).

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:

MAIL STOP SEQUENCE
Commissioner for Patents
Alexandria, VA 22313-1450

on this date, 5/1/03

Dated: 5/1/03


Gail L. Winokur

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
Suite 500, 475 Half Day Road
Lincolnshire, IL 60069 USA